Antifungal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

In recent years, the prevalence of fungal infections has been on the rise, sounding alarm bells across the healthcare industry. Contributing factors to this concerning trend include the rampant increase in global temperatures, widespread chronic illnesses, and immune system issues. Hospital-acquired fungal infections, known as nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, as reported by the Centers for Disease Control and Prevention (CDC). The COVID-19 pandemic further highlighted the risk, with the outbreak of black fungus infections driven by an overwhelming number of hospitalizations. In response, the global antifungal drugs market is witnessing a surge in growth, with market players developing advanced treatment methods, such as azoles, to combat these infections effectively.

Rising Hospitalizations Drive Global Antifungal Drugs Market

The escalating number of hospitalizations is a major driver behind the increasing incidence of fungal infections contracted in healthcare settings. The prevalence of chronic illnesses like cancer and hematopoietic stem cell transplantation, coupled with immune system weaknesses, necessitates frequent hospital visits and stays, significantly raising the risk of nosocomial infections. This trend is especially pronounced in low and middle-income economies, where healthcare infrastructure might be insufficient to prevent such infections. The global antifungal drugs market is expected to flourish in response to this challenging environment.

Azoles-based Medications Demonstrate Remarkable Fungicidal Efficacy

To combat serious and life-threatening fungal infections, numerous medications and treatment methods are under development. One of the most effective groups of fungicidal treatment methods is azoles. Synthetic azoles and semi-synthetic substances have shown considerable efficacy in treating a wide range of fungal infections, including yeast infections, thrush, candidiasis, tinea versicolor, athlete's foot, aspergillosis, ringworm, jock itch, systemic mycosis, and seborrheic dermatitis. Azoles offer a comprehensive spectrum of effectiveness against fungal infections, while maintaining a relatively safer profile with minimal side effects or allergic reactions among patients. Additionally, they are better absorbed by the body and require fewer doses, making them promising contributors to the global antifungal drugs market.

Thriving Healthcare Industry Sustains North America's Market Dominance

North America holds a dominant position in the antifungal drugs market, driven by a high incidence of infectious diseases, chronic illnesses, and a greater rate of hospitalization. The United States, in particular, plays a significant role in contributing to the region's market leadership, thanks to its well-developed pharmaceutical industry and robust research and development activities. The regulatory bodies in the region further foster a favorable business landscape. Meanwhile, the Asia Pacific region is emerging as one of the fastest-growing markets for antifungal drugs, owing to factors such as a rising population, high disposable incomes, widespread drug availability, and a humid climate.

Prominent Players in the Global Antifungal Drugs Market

Leading companies operating in the global antifungal drugs market include: Hologic, Inc., Siemens Medical Solutions USA, Inc., Quest Diagnostics Incorporated, Abbott, BD, Cardinal Health, Inc., bioMerieux SA, F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., and General Electric Company. These market players are actively contributing to advancements in antifungal treatment options to address the growing challenges posed by fungal infections.

As fungal infections continue to pose a significant public health concern, the global antifungal drugs market is poised to witness substantial growth. Advanced treatment methods like azoles hold the promise of better outcomes, fostering a safer and healthier environment for patients worldwide.

1. Executive Summary

1.1. Global Antifungal Drugs Market Snapshot
1.2. Key Market Trends
1.3. Future Projections
1.4. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
  - 2.2.1.1. Driver A
  - 2.2.1.2. Driver B
  - 2.2.1.3. Driver C
- 2.2.2. Restraints
  - 2.2.2.1. Restraint 1
  - 2.2.2.2. Restraint 2
- 2.2.3. Market Opportunities Matrix
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.6. Government Regulations
2.7. Economic Analysis
2.8. PESTLE

3. Global Antifungal Drugs Market Outlook, 2018 - 2030

3.1. Global Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. Imidazole
  - 3.1.1.2. Polyenes
  - 3.1.1.3. Allylamines
  - 3.1.1.4. Echinocandins
  - 3.1.1.5. Other
3.2. Global Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
- 3.2.1. Key Highlights
  - 3.2.1.1. Oral
  - 3.2.1.2. Topical
  - 3.2.1.3. Parenteral
  - 3.2.1.4. Other
- 3.2.2. BPS/Market Attractiveness Analysis
3.3. Global Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 3.3.1. Key Highlights
  - 3.3.1.1. Candidiasis
  - 3.3.1.2. Dermatophytosis
  - 3.3.1.3. Aspergillosis
  - 3.3.1.4. Coccidioidomycosis
  - 3.3.1.5. Other
- 3.3.2. BPS/Market Attractiveness Analysis
3.4. Global Antifungal Drugs Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa
- 3.4.2. BPS/Market Attractiveness Analysis and trends, forming the crux of this section.

4. North America Antifungal Drugs Market Outlook, 2018 - 2030

4.1. North America Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Imidazole
  - 4.1.1.2. Polyenes
  - 4.1.1.3. Allylamines
  - 4.1.1.4. Echinocandins
  - 4.1.1.5. Other
4.2. North America Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Candidiasis
  - 4.2.1.2. Dermatophytosis
  - 4.2.1.3. Aspergillosis
  - 4.2.1.4. Coccidioidomycosis
  - 4.2.1.5. Other
4.3. North America Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. Oral
  - 4.3.1.2. Topical
  - 4.3.1.3. Parenteral
  - 4.3.1.4. Other
4.4. North America Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S.
  - 4.4.1.2. Canada
- 4.4.2. BPS/Market Attractiveness Analysis

5. Europe Antifungal Drugs Market Outlook, 2018 - 2030

5.1. Europe Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. Imidazole
  - 5.1.1.2. Polyenes
  - 5.1.1.3. Allylamines
  - 5.1.1.4. Echinocandins
  - 5.1.1.5. Other
5.2. Europe Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Candidiasis
  - 5.2.1.2. Dermatophytosis
  - 5.2.1.3. Aspergillosis
  - 5.2.1.4. Coccidioidomycosis
  - 5.2.1.5. Other
5.3. Europe Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Topical
  - 5.3.1.3. Parenteral
  - 5.3.1.4. Other
5.4. Europe Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany
  - 5.4.1.2. France
  - 5.4.1.3. U.K.
  - 5.4.1.4. Italy
  - 5.4.1.5. Spain
  - 5.4.1.6. Russia
  - 5.4.1.7. Rest of Europe
- 5.4.2. BPS/Market Attractiveness Analysis

6. Asia Pacific Antifungal Drugs Market Outlook, 2018 - 2030

6.1. Asia Pacific Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018-2030
- 6.1.1. Key Highlights
  - 6.1.1.1. Imidazole
  - 6.1.1.2. Polyenes
  - 6.1.1.3. Allylamines
  - 6.1.1.4. Echinocandins
  - 6.1.1.5. Other
6.2. Asia Pacific Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Candidiasis
  - 6.2.1.2. Dermatophytosis
  - 6.2.1.3. Aspergillosis
  - 6.2.1.4. Coccidioidomycosis
  - 6.2.1.5. Others
6.3. Asia Pacific Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Topical
  - 6.3.1.3. Parenteral
  - 6.3.1.4. Other
6.4. Asia Pacific Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 6.4.1. Key Highlights
  - 6.4.1.1. China
  - 6.4.1.2. Japan
  - 6.4.1.3. South Korea
  - 6.4.1.4. India
  - 6.4.1.5. Southeast Asia
  - 6.4.1.6. Rest of Asia Pacific
- 6.4.2. BPS/Market Attractiveness Analysis

7. Latin America Antifungal Drugs Market Outlook, 2018 - 2030

7.1. Latin America Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. Imidazole
  - 7.1.1.2. Polyenes
  - 7.1.1.3. Allylamines
  - 7.1.1.4. Echinocandins
  - 7.1.1.5. Other
7.2. Latin America Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 7.2.1. Key Highlights
  - 7.2.1.1. Candidiasis
  - 7.2.1.2. Dermatophytosis
  - 7.2.1.3. Aspergillosis
  - 7.2.1.4. Coccidioidomycosis
  - 7.2.1.5. Other
7.3. Latin America Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018-2030
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Topical
  - 7.3.1.3. Parenteral
  - 7.3.1.4. Other
7.4. Latin America Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil
  - 7.4.1.2. Mexico
  - 7.4.1.3. Rest of Latin America
- 7.4.2. BPS/Market Attractiveness Analysis

8. Middle East & Africa Antifungal Drugs Market Outlook, 2018 - 2030

8.1. Middle East & Africa Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. Imidazole
  - 8.1.1.2. Polyenes
  - 8.1.1.3. Allylamines
  - 8.1.1.4. Echinocandins
  - 8.1.1.5. Other
8.2. Middle East & Africa Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Candidiasis
  - 8.2.1.2. Dermatophytosis
  - 8.2.1.3. Aspergillosis
  - 8.2.1.4. Coccidioidomycosis
  - 8.2.1.5. Other
8.3. Middle East & Africa Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Topical
  - 8.3.1.3. Parenteral
  - 8.3.1.4. Other
8.4. Middle East & Africa Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC
  - 8.4.1.2. South Africa
  - 8.4.1.3. Rest of Middle East & Africa
- 8.4.2. BPS/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis
9.2. Competitive Dashboard
9.3. Company Profiles
- 9.3.1. Scynexis, Inc.
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Product Portfolio
  - 9.3.1.3. Financial Overview
  - 9.3.1.4. Business Strategies and Development
- 9.3.2. Pfizer, Inc.
- 9.3.3. Novartis AG
- 9.3.4. Helix Biomedix
- 9.3.5. Sequella, Inc.
- 9.3.6. GILEAD SCIENCES, INC.
- 9.3.7. Leadiant Biosciences, Inc.
- 9.3.8. Sun Pharmaceutical Industries Ltd.
- 9.3.9. Astellas Pharma, Inc.
- 9.3.10. GSK plc
- 9.3.11. Other

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations